You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Midostaurin for untreated acute myeloid leukaemia

  • Technology appraisal guidance
  • Reference number: TA523
  • Published:  13 June 2018
  • Guidance
  • Tools and resources
  • Information for the public
  • History

On this page

  1. Expected publication
  2. Final appraisal determination
  3. Draft guidance: 1
  4. Invitation to participate

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 233 KB)

    Published:
    13 June 2018

Final appraisal determination

  • Final appraisal determination

  • Final appraisal determination document (PDF 356 KB)

    Published:
    04 May 2018
  • Committee papers (PDF 998 KB)

    Published:
    04 May 2018
  • Public committee slides (PDF 372 KB)

    Published:
    04 May 2018
  • Public committee slides (PDF 186 KB)

    Published:
    04 May 2018

Draft guidance: 1

  • Draft guidance: 1

  • Appraisal consultation document (PDF 358 KB)

    Published:
    05 December 2017
  • Committee papers (PDF 19.66 MB)

    Published:
    27 April 2018
  • Public committee slides (PDF 991 KB)

    Published:
    27 April 2018

Invitation to participate

  • Final scope (PDF 224 KB)

    Published:
    12 January 2017
  • Final matrix (PDF 255 KB)

    Published:
    12 January 2017
  • NICE's response to comments on the draft scope and provisional matrix (PDF 332 KB)

    Published:
    12 January 2017
  • Equality impact assessment (Scoping) (PDF 173 KB)

    Published:
    12 January 2017
Back to top